![Page 1: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/1.jpg)
Dalia A. HamdyBPSc, MSc, PhD, RP(ACP), MRSC
5th February [email protected]
Pharmacokinetics and Pharmacodynamics Aspects of
Drugs in Critically Ill PopulationPart I
![Page 2: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/2.jpg)
Dr. Dalia A. Hamdy (FS15AY)2
Learning Objectives1. Describe the changes in critically ill patients that alter drug absorption.
2. Explain how critical illness affects the distribution of drugs.
3. Depict the effects of changing hepatic blood flow and protein binding on drug metabolism.
![Page 3: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/3.jpg)
Dr. Dalia A. Hamdy (FS15AY)3
Learning Objectives.4. Differentiate between different critically ill patient populations and the expected pharmacokinetic (PK) changes.
5. Incorporate the PK changes in a critically ill patient into the design and evaluation of an appropriate drug regimen.
6. Identify the desired pharmacodynamic parametersassociated with efficacy in select drugs.
![Page 4: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/4.jpg)
Dr. Dalia A. Hamdy (FS15AY)4
Session Outline (Part I) Introduction to Clinical Pharmacokinetics and
individualization of therapy
Self Assessment Case
Quick discussion on routes of drug administrations
Critically Ill patients PK alterations in terms of -Absorption-Distribution-Metabolism
![Page 5: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/5.jpg)
Dr. Dalia A. Hamdy (FS15AY)5
References Swanson JM. Updates in Therapeutics®: Critical Care
Pharmacy Preparatory Review Course. 2015 Edition. The American College of Clinical Pharmacy. Pharmacokinetics/Pharmacodynamics Chapter.
Shargel L, Wu-Pong S, Andrew B.C.U. Applied Biopharmaceutics and Pharmacokinetics. 5 th Edition. McGraw-Hil ; 2005
Gibson G and Skett P. Introduction to Drug Metabolism. 3rd Edition. Nelson Thrones ; 2001.
Russel F.G.M. Transporters: Importance in Drug Absorption, Distribution, and Removal. Enzyme- and Transporter-Based Drug-Drug Interactions. Elservier; 2010.
![Page 6: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/6.jpg)
Dr. Dalia A. Hamdy (FS15AY)6
Clinical PharmacokineticsDiscipline that describes ADME of drugs in patients requiring therapy.
![Page 7: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/7.jpg)
Dr. Dalia A. Hamdy (FS15AY)7
Clinical PharmacokineticsIndividualization of Therapy
![Page 8: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/8.jpg)
Dr. Dalia A. Hamdy (FS15AY)8
Clinical Pharmacokinetics
Pharmacokinetics Variability
Effect of Special populations
Effect of different diseases and
conditions
PK drug interactions (ADME)
![Page 9: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/9.jpg)
Dr. Dalia A. Hamdy (FS15AY)9
Special Population: Critically Ill Patients
Why are ICU/critically ill patients considered special population with respect to their drug PK and PD?
![Page 10: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/10.jpg)
Dr. Dalia A. Hamdy (FS15AY)10
Special Population: Critically Ill Patients
Visit Your Patient E.W. is a 48-year-old man (height 70 inches, weight 85 kg) admitted to the trauma ICU after a motorcycle collision. E.W. presents with a traumatic brain injury (TBI; head computed tomography [CT] reveals a depressed skull fracture, frontal subarachnoid hemorrhage, and right intraparenchymal hemorrhage), right acetabulum fracture, bilateral rib fractures, and abdominal trauma. According to his abdominal CT, E.W. must go to the operating room for an exploratory laparotomy to undergo repair of several serosal tears. After surgery, E.W. requires significant resuscitation in his first 24 hours of admission (12 L of normal saline). He is made NPO (nothing by mouth) to allow bowel rest.
![Page 11: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/11.jpg)
Dr. Dalia A. Hamdy (FS15AY)11
Special Population: Critically Ill Patients
Visit Your PatientE.W.’s laboratory values are as follows: serum creatinine (SCr) 1.1 mg/dL, blood urea nitrogen (BUN) 17 mg/dL, and white blood cell count (WBC) 19 × 10cells/mm3. Pulmonary artery catheterization values are cardiac index 4.2 L/minute/m2 (normal 2.8–3.6 L/minute/m) and central venous pressure 9 mm Hg. His medication therapy includes a fentanyl continuous infusion of 75 mcg/hour, a propofol continuous infusion of 15 mcg/kg/minute, pantoprazole 40 mg intravenously every 24 hours, enoxaparin 30 mg subcutaneously every 12 hours, and phenytoin 150 mg intravenously every 8 hours.
![Page 12: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/12.jpg)
Dr. Dalia A. Hamdy (FS15AY)12
![Page 13: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/13.jpg)
Dr. Dalia A. Hamdy (FS15AY)13
![Page 14: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/14.jpg)
Dr. Dalia A. Hamdy (FS15AY)14
![Page 15: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/15.jpg)
Dr. Dalia A. Hamdy (FS15AY)15
Special Population: Critically Ill Patients1. Routes of Administration:
What are the common routes of drugs administration ?
Pros?Cons?
![Page 16: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/16.jpg)
Dr. Dalia A. Hamdy (FS15AY)16
Special Population: Critically Ill Patients1. Routes of Administration:
IV -Bolus
-Infusion
- Most widely used in such population
- F=1, 100% bioavailability- Poor penetration to tissues as
bones, pulmonary and meninges- Septic shock, poor penetration
to subcutaneous and muscle tissues
- Extravasation!
![Page 17: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/17.jpg)
Dr. Dalia A. Hamdy (FS15AY)17
Special Population: Critically Ill Patients1. Routes of Administration:
Oral/Enternal
- Not commonly used in such population
- F<1, bioavailability?!- Variability increase
![Page 18: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/18.jpg)
Dr. Dalia A. Hamdy (FS15AY)18
Special Population: Critically Ill Patients1. Routes of Administration:
Subcutaneous
/Intramuscular
- Escape the first pass, better F than oral
- Still require absorption
![Page 19: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/19.jpg)
Dr. Dalia A. Hamdy (FS15AY)19
Special Population: Critically Ill Patients1. Routes of Administration:
Inhalation
- Commonly used for localized treatment
- To result in higher concentrations at site of action and decrease systemic side effects
- Examples?!
![Page 20: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/20.jpg)
Dr. Dalia A. Hamdy (FS15AY)20
Special Population: Critically Ill Patients1. Routes of Administration:
Intrathecal/intraventric
ular
- Commonly used for localized treatment
- No clinical evidence of superiority over other routes of administration
- Commonly used for treatment of multidrug resistant meningitis
![Page 21: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/21.jpg)
Dr. Dalia A. Hamdy (FS15AY)21
Special Population: Critically Ill Patients1. Routes of Administration:
![Page 22: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/22.jpg)
Dr. Dalia A. Hamdy (FS15AY)22
Special Population: Critically Ill Patients2. AbsorptionClinicians must consider several factors if a route of administration other than intravenous is desired due to bioavailability variations
Bioavailability The rate and extent to which the active ingredients is absorbed and available at systemic circulation
Reminder
![Page 23: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/23.jpg)
Dr. Dalia A. Hamdy (FS15AY)23
Special Population: Critically Ill Patients2. Absorption
Bioavailability
F = AUC test X Dose reference
AUC reference Dose test
If test=IV Absolute BioavailabilityIf test=other route Relative
Bioavailability
Time
Concentration
Ka K Cp Dose
![Page 24: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/24.jpg)
Dr. Dalia A. Hamdy (FS15AY)24
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:1. Hypotension or ShockShifts away the blood from muscles, skin, splanchnic organs to vital ones as brain, heart and lung
-May decrease GIT (oral ) absorption ( no clinical studies evidence yet)
-subcutaneous, transdermal and intramuscular routes?!
![Page 25: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/25.jpg)
Dr. Dalia A. Hamdy (FS15AY)25
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:2. Vasopressor effect Vasopressins (epinephrine, Dopamine,
norepinephrine) - reduces splanchnic blood flow in patients with distributive shock and severe septic shock - Conversely, it results in higher intestinal
perfusion in vasodilatory shock
The variable effect of vasopressors on splanchnic perfusion makes most clinicians abandon the use of orally or enterally administered drugs when vasopressors are being used.
![Page 26: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/26.jpg)
Dr. Dalia A. Hamdy (FS15AY)26
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:2. Vasopressor effect
One study investigated the anti-Xa activity of the low-molecular-weight heparin certoparin in critically ill patients. Less than 50% of patients receiving standard doses of certoparin had anti-Xa activity in the antithrombotic range (0.1–0.3 IU/mL)
Crit Care 2005;9:R541-8
![Page 27: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/27.jpg)
Dr. Dalia A. Hamdy (FS15AY)27
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:3. Intestinal Atrophy- After 3–5 days of fasting, gut mucosal crypt depth and villus height decrease Increase gut permeability- The decreased perfusion worsen this caseThus Increase drug absorption Decrease blood absorption No effect
Discuss!
![Page 28: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/28.jpg)
Dr. Dalia A. Hamdy (FS15AY)28
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. GIT dysmotility- Has an incidence of 60% in such population- This results in delayed gastric emptying
SO? What is expected in the absorption curve profile?
GI dysmotility is generally treated using prokinetic agents such as metoclopramide or erythromycin.
Discuss!
![Page 29: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/29.jpg)
Dr. Dalia A. Hamdy (FS15AY)29
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. GIT dysmotility
![Page 30: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/30.jpg)
Dr. Dalia A. Hamdy (FS15AY)30
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transporters
What are drug transporters?!
![Page 31: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/31.jpg)
Dr. Dalia A. Hamdy (FS15AY)31
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transporters
- Drugs enter to cells through diffusion and active transport.
- Active transport is through transporters (Membrane transport proteins)
- Active transport can be divided into - Primary: does not require ATP- Secondary: uses energy
![Page 32: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/32.jpg)
Dr. Dalia A. Hamdy (FS15AY)32
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transporters
Transporters:- Play a critical role in absorption, distribution, and
excretion of drugs.
- There are two main classes of transporters - Solute carriers (SLC)
- ATP binding cassette (ABC)
![Page 33: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/33.jpg)
Dr. Dalia A. Hamdy (FS15AY)33
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transportersSolute Carriers (SLC) Transporters:Can be further divided into:-- Organic anion transporting peptide (OATp)
- SLCO family of genes - Organic anion transporter (OAT)
- acidic drug transport - Part of SLC22A family of genes
- Organic cation transporter (OCT) - Basic drug transport - Part of SLC22A family of genes
![Page 34: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/34.jpg)
Dr. Dalia A. Hamdy (FS15AY)34
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transportersATP binding cassette (ABC):The subfamilies mostly involved in drug transport are ABCB, ABCC, ABCG examples:
ABCB1 : P-glycoproteins (P-gp)/ Multidrug resistance protein (MDR)
ABCC2: Multidrug resistance associated protein (MRP2)
ABCG2: Breast cancer resistance protein (BCRP)
![Page 35: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/35.jpg)
Dr. Dalia A. Hamdy (FS15AY)35
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transportersTransporters:- Mechanistically they are divided into
- Influx/Uptake transport proteinsImport drugs into the cells and do not usually require energy
- Efflux transportersExport drug out of the cell. Usually against concentration gradient therefore they need energy
![Page 36: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/36.jpg)
Dr. Dalia A. Hamdy (FS15AY)36
Role of transporters in Absorption EnterocytesPEPT1: peptide transporter SLC15A family of genes -Role of P-gp in oral absorption?- Digoxin- Tacrolimus
Role of PEPT1:acyclovir oral bioavailability was enhanced by a factor of 2–3 via its valine ester (valacyclovir), which is a PEPT1 substrate
![Page 37: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/37.jpg)
Dr. Dalia A. Hamdy (FS15AY)37
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:4. Intestinal drug transportersNo PK studies related to effect of critical illness on transporters.
However, inflammatory response syndrome (SIRS) and sepsis affect PGP activity. Therefore, enteral drug absorption has the potential to be altered in these states.
Further studies needs to be pursued.
![Page 38: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/38.jpg)
Dr. Dalia A. Hamdy (FS15AY)38
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:5. Physical incompatibilitiesDrug enteral nutrition interaction-Ciprofloxacin bioavailability decrease when administered with food-levothyroxine, phenytoin, warfarin and voriconazole, reduced absorption
Suggested solution? Your own practice?
![Page 39: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/39.jpg)
Dr. Dalia A. Hamdy (FS15AY)39
Special Population: Critically Ill Patients2. AbsorptionIn critically ill patients:5. Physical incompatibilities-pH changes alters the drug ionization thus their lipophilicity and potentially absorption. -Increased gastric pH caused by histamine-2 receptor antagonists or proton pump inhibitors,
decreased absorption of ketoconazole, itraconazole, atazanavir, cefpodoxime, and dipyridamole.
increased nifedipine ,digoxin and alendronate absorption
Aliment Pharmacol Ther 2009;29:1219-29
![Page 40: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/40.jpg)
Dr. Dalia A. Hamdy (FS15AY)40
Special Population: Critically Ill Patients2. Absorption Clinicians usually avoid enterally administered drugs
because of variability in bioavailability
If the drug is given orally , we can withhold nutrition to avoid physical incompatibilities.
Subcutaneous and intramuscular routes also have similar problems with absorption. However, some clinicians advocate for using larger doses of drugs being administered subcutaneously.
(safety and efficacy studies needs to be further pursued)
Clinical Consideratio
ns
![Page 41: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/41.jpg)
Dr. Dalia A. Hamdy (FS15AY)41
Special Population: Critically Ill Patients2. Absorption
![Page 42: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/42.jpg)
Dr. Dalia A. Hamdy (FS15AY)42
Summary!
![Page 43: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/43.jpg)
Dr. Dalia A. Hamdy (FS15AY) 43
Drug Absorption Distribution
Special Population: Critically Ill Patients
Rate ExtentThe reversible movement of drug from one location to another in the body
3. Distribution
VdDistribution t1/2
![Page 44: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/44.jpg)
Tissue permeability:
Depends on physicochemical properties of drug
Molecular size
Lipid solubility
Drug ionizationDr. Dalia A. Hamdy (FS15AY) 44
Special Population: Critically Ill Patients
Drug Permeability
3. Distribution
![Page 45: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/45.jpg)
Protein BindingPlasma Tissue
Dr. Dalia A. Hamdy (FS15AY) 45
Special Population: Critically Ill Patients
Drug-Protein
Protein + Drug
Elimination
Drug + Protein
Drug-Protein
3. Distribution
![Page 46: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/46.jpg)
Dr. Dalia A. Hamdy (FS15AY)46
Special Population: Critically Ill Patients3. Distribution
Plasma proteins:
Albumin Binds mostly acidic drugs (diazepam, phenytoin)
AAG Binds mostly basic drugs (Lidocaine, diltiazem)
Lipoproteins Binds lipophilic drugs
![Page 47: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/47.jpg)
Dr. Dalia A. Hamdy (FS15AY)47
Special Population: Critically Ill Patients3. Distribution
Vc= Dose/Co
Vc= volume of distribution of central compartmentC0= concentration at zero time
Vdβ= CL/KK= elimination rate constant
Remember : Vd and CL are independent variables
![Page 48: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/48.jpg)
Dr. Dalia A. Hamdy (FS15AY)48
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:Shock states cause the redistribution of blood flow
- perfusion of the muscle, skin, and splanchnic organs.
- Hydrophilic drugs with a smaller Vd (ones that remain in the plasma water volume) may have decreased distribution to parts of the body with decreased blood flow.
Example: Animals with septic shock showed lower gentamicin concentrations in the microcirculation compared with the central vessels.
![Page 49: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/49.jpg)
Dr. Dalia A. Hamdy (FS15AY)49
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:Receiving significant volumes of intravenous fluid for resuscitation purposes.
volumes of total body water and interstitial fluid. Disease states such as sepsis, thermal injury, acute respiratory distress syndrome, AKI, heart failure, and cirrhosis
interstitial fluid volumes. In addition,
![Page 50: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/50.jpg)
Dr. Dalia A. Hamdy (FS15AY)50
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:surgery extracellular volume postoperatively.Thus Vd for hydrophilic drugs and decrease their serum/tissue concentration & Vd for lipophilic drugs
Examples:Compared with healthy volunteers, patients with septic shock had reduced piperacillin tissue concentrations.
![Page 51: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/51.jpg)
Dr. Dalia A. Hamdy (FS15AY)51
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:.
Unfortunately, increased Vd of drugs is not universally noted. Although one study found increases in aminoglycoside Vd, another study was unable to correlate fluid shifts with changes in the aminoglycoside Vd
Crit Care Med 1988;16:327-30
![Page 52: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/52.jpg)
Dr. Dalia A. Hamdy (FS15AY)52
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:. Stress
Albumin
AAG
What will happen?!
![Page 53: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/53.jpg)
Dr. Dalia A. Hamdy (FS15AY)53
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:. The clinical relevance of this was noted
when a decrease in the Vd of lidocaine correlated with an increase in AAG in post-cardiac surgery patients. It was suspected that arrhythmias were caused bythese PK changes
Clin Pharmacol Ther 1984;35:617-26
![Page 54: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/54.jpg)
Dr. Dalia A. Hamdy (FS15AY)54
Special Population: Critically Ill Patients3. Distribution
IMP!
![Page 55: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/55.jpg)
Dr. Dalia A. Hamdy (FS15AY)55
Special Population: Critically Ill Patients3. DistributionIn critically ill patients:pH acid-base disorders are common creating a plasma pH changes that alters the drug ionization thus their lipophilicity and tissue penetration. ionized drug has smaller Vd
Theoretically: drug that is a weak acid in a patient experiencing
acidemia would be expected to have a larger Vd the converse would be true for a basic drug.
Evidence in humans is lacking!
![Page 56: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/56.jpg)
Dr. Dalia A. Hamdy (FS15AY)56
Special Population: Critically Ill Patients3. Distribution
![Page 57: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/57.jpg)
Dr. Dalia A. Hamdy (FS15AY)57
Special Population: Critically Ill Patients3. Distribution
![Page 58: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/58.jpg)
Dr. Dalia A. Hamdy (FS15AY)58
Summary!
![Page 59: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/59.jpg)
4. Metabolism Xenobiotics undergo biotransformation
before being eliminated from our body.
Drug Metabolism, mainly in liver, is usually divided into 2 Phases:
Phase 1: Functionalization reactions (introduction of a functional group)
Phase 2: Conjugative reactions(Conjugation with endogenous compounds)Dr. Dalia A. Hamdy (FS15AY) 59
Special Population: Critically Ill Patients
![Page 60: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/60.jpg)
4. MetabolismPhase 1 metabolism
By introducing or unmasking more polar a functional gp
more readily excretable
Dr. Dalia A. Hamdy (FS15AY) 60
Special Population: Critically Ill Patients
Chemical reactionsOxidationReductionHydrolysisHydrationIsomerizationDethioacetylation
![Page 61: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/61.jpg)
Phase 1 metabolism
Dr. Dalia A. Hamdy (FS15AY) 61
Drug Metabolism
Chemical reactions
Enzymes involved Location
Oxidation Cytochrome P450, Flavin monooxygenase, Alcohol/aldehyde dehydrogenase, Monoamine oxidase
Smooth Endoplasmic reticulum
Reduction
Cytochrome P450, NADPH-cytochrome P450 reductase, carbonyl reductase
Smooth Endoplasmic reticulum
Hydrolysis
Epoxide hydrolase, Amidases Cytosol
![Page 62: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/62.jpg)
4. MetabolismPhase 2 metabolismBy conjugation with an more polar endogenous substance and water
soluble
more readily excretable in
urine or bileDr. Dalia A. Hamdy (FS15AY) 62
Special Population: Critically Ill Patients
Chemical reactionsGlucuronidation/glycosidationSulfationMethylationAcetylationAmino acid conjugationFatty acid conjugation
![Page 63: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/63.jpg)
Phase 2 metabolism
- Conjugation reactions are mostly located in the cytosol except for glucuronidation which occurs in endoplasmic reticulum
1. UDP-Glucuronosyl transferase2. Glutathione S-transferase3. Sulfotransferase4. Amino acid transferase5. N-acetyl transferase6. N-, O-, S- methyl transferase
Dr. Dalia A. Hamdy (FS15AY) 63
Drug Metabolism
![Page 64: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/64.jpg)
Cytochrome P450-Dependant Mixed Function Oxidation Reactions:Mixed function oxidases are membrane proteins compose of
- CYP P450- NADPH dependent CYP P450- Phospholipids
Dr. Dalia A. Hamdy (FS15AY) 64
Drug Metabolism
![Page 65: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/65.jpg)
Cytochrome P450-Dependant Mixed Function Oxidation Reactions:
Dr. Dalia A. Hamdy (FS15AY) 65
Drug Metabolism
![Page 66: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/66.jpg)
Cytochrome P450-Dependant Mixed Function Oxidation Reactions:
CYP P450:- Terminal oxidase component of an
electron transfer system present in ER
RH ROH- It is a haem-containing enzyme
(haemoprotein called protoporphyrin IX)
Dr. Dalia A. Hamdy (FS15AY) 66
Drug Metabolism
![Page 67: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/67.jpg)
Cytochrome P450-Dependant Mixed Function Oxidation Reactions:
CYP P450:
- Nomenclature is derived from the fact that the cytochrome exhibits a spectral absorbance maximum at 450 nm when reduced Fe(II) heme binds to CO.
- Is a family of enzymes rather than a single enzyme
Dr. Dalia A. Hamdy (FS15AY) 67
Drug Metabolism
![Page 68: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/68.jpg)
Cytochrome P450-Dependant Mixed Function Oxidation Reactions:CYP P450 Nomenclature :
- Family: CYP + Arabic numerical (share > 40% homology of amino acid sequence ex: CYP1 , CYP2, CYP3..etc)
- Subfamily: Additional letter (share > 55% homology of amino acid sequence ex: CYP1A , CYP2D, CYP3A..etc)
- Isoenzyme : Additional Arabic number ex: CYP3A4
Dr. Dalia A. Hamdy (FS15AY) 68
Drug Metabolism
![Page 69: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/69.jpg)
Cytochrome P450-Dependant Mixed Function Oxidation Reactions:CYP P450 Nomenclature :
- Italics indicates genes (CYP3A4)
- Regular fonts indicate enzymes (CYP3A4)
- Small letters indicate mouse enzymes (cyp1a1)
http://study.hiberniacollege.net/novartis/2014/novartis_clpap/session3/task0/novartis_clpap_s3_t0_s3/presentation.html
Dr. Dalia A. Hamdy (FS15AY) 69
Drug Metabolism
![Page 70: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/70.jpg)
4. MetabolismRenal Metabolism – There is evidence that the kidneys express the CYP isoenzymes 2B6, 3A5, 1A9, 2B7. CYP 2C8, 2C9, and 3A4. are also expressed in
the kidneys. In addition, UGT (UDPglucuronosyltransferase)
No data related to effect of critical illness on such kidney enzymes
Dr. Dalia A. Hamdy (FS15AY) 70
Special Population: Critically Ill Patients
![Page 71: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/71.jpg)
4. MetabolismRenal Metabolism – Critically ill patients with AKI have clinically relevant changes in insulin metabolism, as evidenced by increased hypoglycemic events and lower insulin requirements upon developing AKI
(Nutrition 2011;27:766-72).
Dr. Dalia A. Hamdy (FS15AY) 71
Special Population: Critically Ill Patients
![Page 72: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/72.jpg)
4. MetabolismHepatic Metabolism
Hepatic ClearanceCLT= CLr + CL nr
=CLr + CLH + CL other
Dr. Dalia A. Hamdy (FS15AY) 72
Special Population: Critically Ill Patients
Hepatic clearance
First PassPortal vein
Hepatic ClearanceHepatic artery
![Page 73: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/73.jpg)
Extraction ratio (E)The fraction of the drug that is extracted
(removed) by the organ upon each pass of blood through the organ
E= (Cin-Cout)/(Cin)
Dr. Dalia A. Hamdy (FS15AY) 73
Liver CoutCin
Special Population: Critically Ill Patients
![Page 74: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/74.jpg)
Extraction ratio (E)
Factors affecting rate of drug extraction by organ:
1. Blood Flow (Q)2. Intrinsic ability of organ to remove drug(Number and affinity of enzymes)
CLorgan= Q. E
Q of liver is 1500 mL/min in a healthy 70 Kg man (learn)Dr. Dalia A. Hamdy (FS15AY) 74
Special Population: Critically Ill Patients
![Page 75: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/75.jpg)
Hepatic extraction ratio is dependant on the1. Hepatic Blood Flow (Q)2. Clearance intrinsic:Maximum volume of blood that could be cleared
from drug over a period of time
E= CLint/(Q+CLint)
CLorgan= Q. CLint
Dr. Dalia A. Hamdy (FS15AY) 75
Special Population: Critically Ill Patients
Q+CLin
t
![Page 76: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/76.jpg)
Hepatic Clearance and unbound fraction
Organ Clearance is dependant on unbound fraction
WHY?
Dr. Dalia A. Hamdy (FS15AY) 76
Special Population: Critically Ill Patients
![Page 77: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/77.jpg)
Hepatic Clearance and unbound fraction
Organ Clearance is dependant on unbound fraction
CLint = fu . CLint’
CLint = intrinsic clearance total (unbound+bound)fu = unbound fractionCLint’= intrinsic clearance for unbound drug
Dr. Dalia A. Hamdy (FS15AY) 77
Special Population: Critically Ill Patients
![Page 78: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/78.jpg)
Hepatic Clearance and unbound fraction
Dr. Dalia A. Hamdy (FS15AY) 78
Special Population: Critically Ill Patients
CLhepatic= Q. fu.CLint’Q+ fu.CLint’
![Page 79: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/79.jpg)
Classification of E
1. High E > 0.72. Intermediate E between 0.3 and
0.73. Low E < 0.3
Dr. Dalia A. Hamdy (FS15AY) 79
Special Population: Critically Ill Patients
![Page 80: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/80.jpg)
1. High E > 0.7
Clhepatic = Q. CLint
Dr. Dalia A. Hamdy (FS15AY) 80
Special Population: Critically Ill Patients
Q+ CLint
Clint>>>>>Q
![Page 81: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/81.jpg)
1. low E < 0.3
Clhepatic = Q. CLint
Dr. Dalia A. Hamdy (FS15AY) 81
Special Population: Critically Ill Patients
Q+ CLint
Q>>>>>CLint
fu.CLint’
![Page 82: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/82.jpg)
Relationship between E and FF=1-ER
F = hepatic Bioavailability
E = Hepatic extraction ratio
Dr. Dalia A. Hamdy (FS15AY) 82
Special Population: Critically Ill Patients
![Page 83: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/83.jpg)
Dr. Dalia A. Hamdy (FS15AY)83
High Extraction Ratio Drugs Discuss
![Page 84: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/84.jpg)
Dr. Dalia A. Hamdy (FS15AY)84
Low Extraction Ratio Drugs Discuss
![Page 85: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/85.jpg)
1. Increased hepatic blood flow2. Decreased hepatic blood flow
-Low cardiac ourput In hypovolemia or hemorrahgic shock, myocardial
infarction, acute heart failure
-Mechanical ventilation increase intrathoracic pressure, thus decrease venous return to the heart, compresses the ventricles, and reduces ventricular filling.The result is a decrease in cardiac output and hepatic blood flow
-Adding inotropic improves hepatic blood flow
Dr. Dalia A. Hamdy (FS15AY) 85
Special Population: Critically Ill Patients
![Page 86: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/86.jpg)
Dr. Dalia A. Hamdy (FS15AY)86
End of Part I
![Page 87: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/87.jpg)
Dalia A. HamdyBPSc, MSc, PhD, RP(ACP), MRSC
12th February [email protected]
Pharmacokinetics and Pharmacodynamics Aspects of
Drugs in Critically Ill PopulationPart II
![Page 88: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/88.jpg)
Dr. Dalia A. Hamdy (FS15AY)88
Session Outline (Part II) Critically Ill patients PK alterations in terms of --Elimination
Pharmacodynamics of drugs and special considerations in critically ill patients
Quick overview of TDM
Solving questions
![Page 89: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/89.jpg)
1. Increased hepatic blood flowCritically ill patients in the hyperdynamic phase of sepsis or septic shock have an increased cardiac output and increased hepatosplanchnic blood flow.
However, This was not confirmed in all studied, Thus
such patients are left with a potential of……..?
Dr. Dalia A. Hamdy (FS15AY) 89
Special Population: Critically Ill Patients
![Page 90: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/90.jpg)
2. Decreased hepatic blood flow
-Low cardiac ourput In hypovolemia or hemorrahgic shock, myocardial
infarction, acute heart failure
-Mechanical ventilation increase intrathoracic pressure, thus decrease venous return to the heart, compresses the ventricles, and reduces ventricular filling.The result is a decrease in cardiac output and hepatic blood flow
-Adding inotropic (ex. Dobutamine) improves hepatic blood flow
Dr. Dalia A. Hamdy (FS15AY) 90
Special Population: Critically Ill Patients
![Page 91: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/91.jpg)
Dr. Dalia A. Hamdy (FS15AY)91
Special Population: Critically Ill Patients3. Effect of Changes in Intrinsic Clearance- Drug interactions Critically ill patients do not have major altered intrinsic clearance
However, polypharmacy, complex pharmacotherapeutic regimens, in such patients can result in drug interactions
Many drugs used in critically ill patients are substrates, inducers, inhibitors, or combinations of these.
![Page 92: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/92.jpg)
Dr. Dalia A. Hamdy (FS15AY)92
Special Population: Critically Ill Patients3. Effect of Changes in Intrinsic Clearance-Drug interactions Inflammation : SIRS, Systemic Inflammatory response syndrome, Early sepsis, increase inflammation.
-The inflammatory cytokines interleukin (IL)-1α, IL-6, and TNFα (tumor necrosis factor alpha) decrease the expression and activity of CYP enzymes.
Effect?? Discuss
![Page 93: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/93.jpg)
Dr. Dalia A. Hamdy (FS15AY)93
Special Population: Critically Ill Patients3. Effect of Changes in Intrinsic Clearance-Hypothermia – Animal models have shown that hypothermia affects drugs metabolized through the CYP system.
Phenytoin PK showed increased concentration and reduced metabolism during mild hypothermia but no changes in protein binding. (Ther Drug Monit 2001;23:192-7)
Midazolam, fentanyl, remifentanil, phenobarbital, and vecuronium have decreased hepatic clearance during hypothermia..
Discuss
![Page 94: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/94.jpg)
Dr. Dalia A. Hamdy (FS15AY)94
Special Population: Critically Ill Patients3. Effect of Changes in Intrinsic Clearance- AKI – AKI results in impaired CYP3A activity
Example Patients with worsening AKI, as determined using the RIFLE (risk, injury, failure, loss) criteria, had increasingmidazolam concentrations.
(Intensive Care Med 2012;38:76-84)
![Page 95: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/95.jpg)
Dr. Dalia A. Hamdy (FS15AY)95
Special Population: Critically Ill Patients3. Effect of Changes in Intrinsic ClearanceNote
Critically ill patients generally have more than one changeoccurring at the same time.
Septic shock patients have -increased hepatic blood flow, increased cardiac output
-inflammation and decreased intrinsic clearance .The clinician needs to monitor patients and be ware of potential toxicities
This would affect who?? Discuss
![Page 96: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/96.jpg)
Dr. Dalia A. Hamdy (FS15AY)96
Special Population: Critically Ill Patients
![Page 97: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/97.jpg)
Dr. Dalia A. Hamdy (FS15AY)97
Special Population: Critically Ill Patients
![Page 98: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/98.jpg)
Dr. Dalia A. Hamdy (FS15AY)98
Special Population: Critically Ill Patients
![Page 99: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/99.jpg)
Dr. Dalia A. Hamdy (FS15AY)99
Special Population: Critically Ill Patients
![Page 100: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/100.jpg)
Dr. Dalia A. Hamdy (FS15AY)100
Summary!
![Page 101: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/101.jpg)
5. ExcretionA. Renal Excretion:The processes by which drug is excreted:
1. Glomerular Filtration
2. Active Secretion
3. Tubular reabsorption
ICU patients clinical condition result in altered renal excretion
Dr. Dalia A. Hamdy (FS15AY) 101
Special Population: Critically Ill Patients
![Page 102: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/102.jpg)
5. ExcretionA. Renal Excretion:1. Filtration GFR is used to describe kidney function. The National Kidney Foundation defines normal kidney function as
140 ± 30 mL/minute/1.73m2 for young healthy men126 ± 22 mL/minute/1.73m2 for young healthy women
Dr. Dalia A. Hamdy (FS15AY) 102
Special Population: Critically Ill Patients
![Page 103: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/103.jpg)
5. ExcretionA. Renal Excretion:1. FiltrationCL due to glomerular filtration CLgf
CLgf= fu X GFR
fu= unbound fraction
Dr. Dalia A. Hamdy (FS15AY) 103
Special Population: Critically Ill Patients
![Page 104: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/104.jpg)
Dr. Dalia A. Hamdy (FS15AY)104
Dose adjustment in Renal and hepatic diseases
![Page 105: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/105.jpg)
Measurement of glomerular filtration rate
1. Inulin: Fructose polysaccharide, a standard
reference for measurement of GFR
However, time consuming procedures
Thus not frequently used in clinical practice
Dr. Dalia A. Hamdy (FS15AY) 105
Dose adjustment in Renal and hepatic diseases
![Page 106: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/106.jpg)
Measurement of glomerular filtration rate2. Creatinine clearance
Extensively used as measure for GFR
Creatinine: an endogenous substance formed during muscle metabolism. Varies according to age, weight, and gender Filtered mainly at the glomerulus , no renal reabsorption but
small amount is actively secreted.
GFR values from CLcr > that obtained from inulin
Dr. Dalia A. Hamdy (FS15AY) 106
Dose adjustment in Renal and hepatic diseases
![Page 107: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/107.jpg)
Dr. Dalia A. Hamdy (FS15AY)107
![Page 108: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/108.jpg)
5. ExcretionA. Renal Excretion:
1. FiltrationIn critically ill patientssurgery, trauma, burns, and sepsis
Increased cardiac output and vasodilatation
Increased renal blood flow Thus?
Dr. Dalia A. Hamdy (FS15AY) 108
Special Population: Critically Ill Patients
![Page 109: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/109.jpg)
5. ExcretionA. Renal Excretion:1. Glomerular hyperfiltration (CrCl elevated)
2. Vancomycin, ciprofloxacin, imipenem, fluconazole, and aminoglycoside renal elimination was found to increase in burn patients
Dr. Dalia A. Hamdy (FS15AY) 109
Special Population: Critically Ill Patients
![Page 110: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/110.jpg)
5. ExcretionA. Renal Excretion:
3. Fluid administration improve cardiac output and thus renal blood flow in animals but not in humans
4. Vasoactive drugs, vassopressors, norepinephrine; would be expected to improve cardiac output and thus renal blood flow.
Dr. Dalia A. Hamdy (FS15AY) 110
Special Population: Critically Ill Patients
![Page 111: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/111.jpg)
5. ExcretionA. Renal Excretion:Impaired renal function
Critically ill patients have 78% incidence of AKIDecreased renal excretion of drugs
Dr. Dalia A. Hamdy (FS15AY) 111
Special Population: Critically Ill Patients
![Page 112: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/112.jpg)
5. ExcretionA. Renal Excretion:Impaired renal function
Dr. Dalia A. Hamdy (FS15AY) 112
Special Population: Critically Ill Patients
![Page 113: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/113.jpg)
5. ExcretionA. Renal Excretion:Impaired renal function
Dr. Dalia A. Hamdy (FS15AY) 113
Special Population: Critically Ill Patients
![Page 114: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/114.jpg)
5. ExcretionA. Renal Excretion:Impaired renal function
As per the updated guidelines, It is important to have at least one GFR estimate for all patients.
Dr. Dalia A. Hamdy (FS15AY) 114
Special Population: Critically Ill Patients
![Page 115: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/115.jpg)
5. ExcretionA. Renal Excretion:Secretion and reabsorption:
No data about important clinical variability in critically ill patients
Dr. Dalia A. Hamdy (FS15AY) 115
Special Population: Critically Ill Patients
![Page 116: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/116.jpg)
5. ExcretionA. Renal Excretion: AKI Patients may undergo hemodialysis. Drug removal by dialysis depends on the method of
dialysis used.
Acute intermittent hemodialysisIntermittent hemodialysis can significantly remove drugs that are not much removed by regular hemodialysis
Drug removal depends on physicochemical properties of the drug as well as equipment used Discuss!Dr. Dalia A. Hamdy (FS15AY) 116
Special Population: Critically Ill Patients
![Page 117: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/117.jpg)
5. ExcretionA. Renal Excretion:Renal Replacement therapyContinuous renal replacement therapies (CRRTs)CRRT refers to several methods of renal replacement.
Dr. Dalia A. Hamdy (FS15AY) 117
Special Population: Critically Ill Patients
Dosen = normal dose of a drug, Qeff = effluent rate, SC = sieving coefficientClnorm= normal clearance of the drug nonrenal
![Page 118: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/118.jpg)
Dr. Dalia A. Hamdy (FS15AY)118
Extracorporeal removal of drugs: Dialysis
Dialysance: is a clearance term process of drug removal from the dialysis machine
CLD= Q(Ca-Cv)/(Ca)
CLD= dialysance, dialysis clearanceQ= rate of blood flow in kidney machineCa= drug concentration in arterial blood (blood entering the
machine)Cv= drug concentration in venous blood (blood leaving the machine)
Dose adjustment in Renal diseases
![Page 119: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/119.jpg)
Dr. Dalia A. Hamdy (FS15AY)119
Extracorporeal removal of drugs: Dialysis
The average plasma drug concentration
Css average= FD/(CLT+ CLD )τ
CLD= dialysance, dialysis clearanceCLT= Total ClearanceF= fraction of dose absorbedτ= dosing intervalD= dose
Dose adjustment in Renal diseases
![Page 120: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/120.jpg)
5. ExcretionB. Hepatic Excretion:Hepatic excretion of drugs is less important for most drugs than renal excretion. It can be affected by critical illness sp. for some
neuromuscular blocking agents.
Nine patients undergoing surgery for total biliary obstruction showed a significant increase in pancuronium half-life compared with normal patients with no change in urinary excretion of pancuronium and its metabolites.
(Br J Anaesth 1977;49:1103-8).Dr. Dalia A. Hamdy (FS15AY) 120
Special Population: Critically Ill Patients
![Page 121: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/121.jpg)
5. ExcretionB. Hepatic Excretion:
Similar results were found for vecuronium in patients with cholestasis, where the mean half-life was 98 minutes in patients with cholestasis and 58 minutes in normal patients (Br J Anaesth 1986;58:983-7).
Dr. Dalia A. Hamdy (FS15AY) 121
Special Population: Critically Ill Patients
![Page 122: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/122.jpg)
5. ExcretionC. Pulmonary Excretion
Pulmonary excretion is important for volatile gases such as anesthetics. Acute respiratory distress syndrome
impaired gas exchange affects body’s ability to remove volatile
gases
- No data regarding ability of critically ill patients to excrete anesthetics.
Dr. Dalia A. Hamdy (FS15AY) 122
Special Population: Critically Ill Patients
![Page 123: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/123.jpg)
6. Pharmacodynamics
-Is the biochemical and physiologic effects of a drug, “Mechanism of action”, “drug/receptor binding and clinical effect”
- Effect can sometimes be measurable as blood pressure or unmeasurable as the gastric pH
Dr. Dalia A. Hamdy (FS15AY) 123
Special Population: Critically Ill Patients
![Page 124: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/124.jpg)
6. Pharmacodynamics
Sigmoid Emax model
Emax: maximal effectEC50: plasma conc needed to get 50% Emax
Dr. Dalia A. Hamdy (FS15AY) 124
Special Population: Critically Ill Patients
concentration
Effec
t
![Page 125: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/125.jpg)
6. Pharmacodynamics
Sigmoid Emax model
(Hill equation)Effect = Emax. Cn
n= shape factor
Dr. Dalia A. Hamdy (FS15AY) 125
Special Population: Critically Ill Patients
concentration
Effec
tEC50 + Cn
![Page 126: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/126.jpg)
6. Pharmacodynamics
Sigmoid Emax model
(Hill equation)Effect = Emax. Cn
n= 1 simple Emax model
Dr. Dalia A. Hamdy (FS15AY) 126
Special Population: Critically Ill Patients
concentration
Effec
tEC50 + Cn
![Page 127: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/127.jpg)
6. PharmacodynamicsAntibioticsgenerally fall into three PD categories, (1) time-dependent killing (T>MIC), (2) Concentrationdependent killing (Cmax/MIC)(3) a combination of time- and concentration-dependent killing (AUC/MIC).
Dr. Dalia A. Hamdy (FS15AY) 127
Special Population: Critically Ill Patients
![Page 128: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/128.jpg)
6. PharmacodynamicsAntibiotics β-Lactam antibiotics: A percentage of time the free drug concentration remains above the MIC. (fT>MIC) needs to be 100%. However, For critically ill patients it is assumed to have
suggested breakpoint ranges from 50% to 100% (fT>MIC) (Br J Clin Pharmacol 2012;73:27-36).
Dr. Dalia A. Hamdy (FS15AY) 128
Special Population: Critically Ill Patients
![Page 129: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/129.jpg)
6. PharmacodynamicsAntibiotics β-Lactam antibiotics: -Many institutions have adopted the practice of prolonged or continues infusions.
-Modelling can be used but there is still discrepancies between modelling results and clinical trails results in such population
Dr. Dalia A. Hamdy (FS15AY) 129
Special Population: Critically Ill Patients
![Page 130: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/130.jpg)
6. PharmacodynamicsAntibioticsAminoglycosides: -Gentamicin,Tobramycin, Amikacin, netilmicin Efficacy: concentration-dependent killing.
(Cmax/MIC). Peak-to-MIC ratios of 8–10 resulted in around
90% clinical response (J Infect Dis 1987;155:93-9).-Postantibiotic effect :A phenomena of continued bacterial killing when Css < MIC
Dr. Dalia A. Hamdy (FS15AY) 130
Special Population: Critically Ill Patients
![Page 131: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/131.jpg)
6. PharmacodynamicsAntibiotics Aminoglycosides: once-daily aminoglycoside dosing has been used. Taking advantage of high peak concentrations maximizes the PD of aminoglycosides.
Critically ill patients show Vd variability as well as ARC raises issues about appropriately dosing these agents, especially in critically injured trauma patients, whose drug levels can be undetectable for more than 12 hours (J Trauma 2000;49:869-87)Dr. Dalia A. Hamdy (FS15AY) 131
Special Population: Critically Ill Patients
TDM? Side effects? EfficacyPractice!
![Page 132: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/132.jpg)
Dr. Dalia A. Hamdy (FS15AY)132
Aminoglycosides
What do we monitor?-Peak and trough levels-Serum creatinine (in renal insufficiency)
TDM
-Ototoxicity (irreversible)-Nephrotoxicity (reversible)
![Page 133: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/133.jpg)
6. PharmacodynamicsAntibiotics Vancomycin: Current guidelines use the available literature to recommend an AUC/MIC of 400 or greater
(Am J Health Syst Pharm 2009;66:82-98).
The guidelines suggest that continuous-infusion regimens are unlikely to improve patient outcomes and that standard intermittent infusions should be sufficient to achieve the desired PD end pointsDr. Dalia A. Hamdy (FS15AY) 133
Special Population: Critically Ill Patients
TDM? Side effects? EfficacyPractice!
![Page 134: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/134.jpg)
6. PharmacodynamicsAntibiotics Vancomycin: However in critically ill patients, vancomycin-associatedNephrotoxicity was reported with intermittent dosing rather than continuous infusion (odds ratio 8.2; p≤0.001)
(Crit Care Med 2014;42:2527-36).
Dr. Dalia A. Hamdy (FS15AY) 134
Special Population: Critically Ill Patients
TDM? Side effects? EfficacyPractice!
![Page 135: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/135.jpg)
6. PharmacodynamicsAntibiotics Vancomycin:
critically injured trauma patients being treated for ventilator-associated pneumonia require aggressive dosing as high as 20 mg/kg administered as often as every 6 hours were needed to optimize PK parameters
(J Trauma Acute Care Surg 2012;72:1478-83).
Dr. Dalia A. Hamdy (FS15AY) 135
Special Population: Critically Ill Patients
TDM? Side effects? EfficacyPractice!
![Page 136: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/136.jpg)
Dr. Dalia A. Hamdy (FS15AY)136
VancomycinDose:1. Estimate creatinine clearance2. For very sick patients Loading dose of 20-25 mg/KgFollowed by Maintenance dose based on actual body weight (ABW) and nomograms
TDM
OtotoxicityNephrotoxicityRed-man syndrome
![Page 137: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/137.jpg)
Dr. Dalia A. Hamdy (FS15AY)137
VancomycinDose: TDM
OtotoxicityNephrotoxicityRedman syndrome
![Page 138: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/138.jpg)
Dr. Dalia A. Hamdy (FS15AY)138
VancomycinDose: TDM
OtotoxicityNephrotoxicityRedman syndrome
![Page 139: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/139.jpg)
Dr. Dalia A. Hamdy (FS15AY)139
VancomycinDrug interactions: Pharmacodynamic rather than PK
+Aminoglycosides = nephrotoxicity
+warfarin= augmented hypothrombinemic effect
![Page 140: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/140.jpg)
6. Pharmacodynamics
Anticoagulants
Concern for a variable response in critically ill patients has led to the development of dosing nomograms/protocols. Researchers have found a shortened time to therapeutic aPTTs in critically ill patients receiving unfractionated heparin and direct thrombin inhibitors (argatroban and bivalirudin).
Dr. Dalia A. Hamdy (FS15AY) 140
Special Population: Critically Ill Patients
![Page 141: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/141.jpg)
6. PharmacodynamicsGeneral tendencymost PD studies of drugs have shown a decreased response in critically ill patients. For example, septic shock patients have reduced response to dobutamine Trauma patients with edema have lower AUCs for anti-Xa activity
Dr. Dalia A. Hamdy (FS15AY) 141
Special Population: Critically Ill Patients
![Page 142: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/142.jpg)
7. Therapeutic Drug MonitoringTherapeutic drug monitoring (TDM) refers to the measurement of medication concentrations in theBlood
TO(1) maximize efficacy(2) reduce toxicity.
Dr. Dalia A. Hamdy (FS15AY) 142
Special Population: Critically Ill Patients
When???
![Page 143: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/143.jpg)
143
Is about using Plasma/serum drug concentrations, PK, PD for
Dr. Dalia A. Hamdy (FS15AY)
Therapeutic Drug Monitoring(TDM)
![Page 144: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/144.jpg)
144
Is a multidisciplinary function involving
Scientists, Clinicians, Nurses and Pharmacists
Dr. Dalia A. Hamdy (FS15AY)
Therapeutic Drug Monitoring(TDM)
ALL Drug
s?
![Page 145: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/145.jpg)
145
TDM is specifically important For drugs having narrow therapeutic index
Dr. Dalia A. Hamdy (FS15AY)
Therapeutic Drug Monitoring(TDM)
MEC
MTC
![Page 146: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/146.jpg)
146
Drug Therapeutic RangeDigoxin 0.5-2 ng/mLLidocaine 1.5-5 ug/mLGentamicin, tobramycin, netilimicin
5-10 ug/mL (peak), <2ug/mL (trough)
Vancomycin 20-40 ug/mL (peak), 5-10 ug/mL (trough)
Phenytoin 10-20 ug/mLphenobarbital 15-40 ug/mLCyclosporine 150-400 ng/mL (blood)Theophylline 10-20 ug/mLlithium 0.6-1.4 mEq/L
Dr. Dalia A. Hamdy (FS15AY)
Therapeutic Drug Monitoring(TDM)
![Page 147: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/147.jpg)
Dr. Dalia A. Hamdy (FS15AY)147
Special Population: Critically Ill Patients In critically ill patients TDM is very important
for few drugs Example
![Page 148: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/148.jpg)
Dr. Dalia A. Hamdy (FS15AY)148
Special Population: Critically Ill Patients
![Page 149: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/149.jpg)
Dr. Dalia A. Hamdy (FS15AY)149
Special Population: Critically Ill PatientsIndividualization of therapy is quite importantTo calculate half life?
![Page 150: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/150.jpg)
Dr. Dalia A. Hamdy (FS15AY)150
Special Population: Critically Ill PatientsIndividualization of therapy is quite importantWhy Cmax and Cmin?
![Page 151: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/151.jpg)
Dr. Dalia A. Hamdy (FS15AY)151
Special Population: Critically Ill PatientsIndividualization of therapy is quite important
![Page 152: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/152.jpg)
Dr. Dalia A. Hamdy (FS15AY)152
Special Population: Critically Ill PatientsIndividualization of therapy is quite important
DRUG REGIMEN and Dose Modification
Discuss!
![Page 153: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/153.jpg)
Dr. Dalia A. Hamdy (FS15AY)153
Special Population: Critically Ill PatientsIndividualization of therapy is quite importantNomograms?!
![Page 154: PK & PD Aspects of drugs in critically ill population](https://reader031.vdocument.in/reader031/viewer/2022013005/5878dcc51a28ab917a8b7511/html5/thumbnails/154.jpg)
Dr. Dalia A. Hamdy (FS15AY)154
Good Luck